alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
---

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Edwin Chan, hereby certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:

|(1) | the Annual Report on Form 10-K of China Health Care
      Corporation for the year ended September 30, 2008(the "Report") fully
      complies with the requirements of Section 13(a) or 15(d) of the Securities
      Exchange Act of 1934; and
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                                                                                                                 
|(2) | the information contained in the Report fairly presents,
      in all material respects, the financial condition and results of
      operations of China Health Care Corporation.                                                              

Dated: December 29, 2008

| | /s/
      Edwin Chan                      
| | ------------------------------------------
| | Edwin Chan                                
| | Chief Financial Officer                   
| | (Principal Financial Officer and Principal
| | Accounting Officer)                       
| | China Health Care Corporation             

A signed original of this written statement required by
Section 906, or other document authenticating, acknowledging, or otherwise
adopting the signature that appears in typed form within the electronic version
of this written statement required by Section 906, has been provided to China
Health Care Corporation and will be retained by China Health Care Corporation
and furnished to the Securities and Exchange Commission or its staff upon
request.

---
No. 63963.

protest 59/26553 (New York).

#### Manca, Inc. *v.*United States,

Opinion by

Oliver, C. J.

In accordance with stipulation of counsel that the merchandise consists of cameras, the claim of the plaintiff was sustained.
# C_2019376EN.01004101.xml

| 6.11.2019 | EN | Official Journal of the European Union | C 376/41 |
| --- | --- | --- | --- |

6.11.2019

EN

Official Journal of the European Union

C 376/41

---

Fuel Cells and Hydrogen 2 Joint Undertaking

Publication of the final accounts for the financial year 2018

(2019/C 376/41)

The complete version of the final accounts may be found at the following address:

https://www.fch.europa.eu/page/budget-and-annual-accounts

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).                    

*Date:*                         November 14, 2023.                    

*Time:*                         1:00 p.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G45, Rockville, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Vanitha S. Raman, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G45, Rockville, MD 20852, 301-761-7949,                         *vanitha.raman@nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: October 17, 2023.

David Freeman, 

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-23232 Filed 10-19-23; 8:45 am]

BILLING CODE 4140-01-P
<PAGE>   1
                                                                      EXHIBIT 23


INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in Registration Statement No.
333-10157 of The Dial Corporation on Form S-8 of our report dated June 7, 1999,
appearing in the Annual Report on Form 11-K of The Dial Corporation 401(k) Plan
for Hourly Employees for the eleven-month period ended November 30, 1998.

\s\ Deloitte & Touche LLP
-------------------------
Deloitte & Touche LLP

Phoenix, Arizona
June 7, 1999


                                       14
**KPMG
      LLP**


55
      Second
      Street


San
      Francisco, CA 94105




**Independent
      Accountants' Report**


The
      Board
      of Directors


North
      Fork Bancorporation, Inc.:




We
      have
      examined management's assertion, included in the accompanying Management
      Assertion, that GreenPoint
      Mortgage Funding, Inc., a wholly owned subsidiary of North Fork Bancorporation,
      Inc., complied
      with the minimum servicing standards set forth in the Mortgage Bankers
      Association of America's *Uniform
      Single Attestation Program for Mortgage Bankers* (USAP)
      as
      of and for the year ended December 31, 2005. Management is responsible for
      GreenPoint Mortgage Funding, Inc.'s compliance with those minimum servicing
      standards. Our responsibility is to express an opinion on management's assertion
      about GreenPoint Mortgage Funding, Inc.'s compliance based on our
      examination.




Our
      examination was conducted in accordance with attestation standards established
      by the American Institute
      of Certified Public Accountants and, accordingly, included examining, on a
      test
      basis, evidence about
      GreenPoint Mortgage Funding, Inc.'s compliance with the minimum servicing
      standards specified above
      and
      performing such other procedures as we considered necessary in the
      circumstances. We believe that
      our
      examination provides a reasonable basis for our opinion. Our examination does
      not provide a legal determination
      on GreenPoint Mortgage Funding, Inc.'s compliance with the minimum servicing
      standards.




Our
      examination disclosed the following material noncompliance with minimum
      servicing standards over custodial bank accounts as of and for the year ended
      December 31, 2005. Certain custodial bank account reconciliations
      were not prepared and reviewed on a timely basis. In addition, there are certain
      custodial bank accounts that have reconciling items that have not been resolved
      within 90 calendar days of their original
      identification.




In
      our
      opinion, except for the material noncompliance described in the third paragraph,
      GreenPoint Mortgage
      Funding, Inc. complied, in all material respects, with the aforementioned
      minimum servicing standards
      as of and for the year ended December 31, 2005.




/s/
      KPMG
      LLP




February
      21, 2006




KPMG
      LLP, a
      U.S. limited liability partnership, of the U.S.


member firm
      of
      KPMG International, a Swiss cooperative.
Amendment to Employment Agreement



 Exhibit 10.37 
  
 Amendment to Employment Agreement Dated May 10th, 1999 
  
 Amendment is officially effective as of
Monday July 28th, 2003, between Proflowers (Company) and Jonathan Sills (Executive). 
  
 The company and Executive desire to amend certain terms and conditions set forth in the
original agreement dated May 10th, 1999. 
  
 The following are the amendments to the original agreement. Outside of the listed changes below, all other aspects contained within each
section of the original agreement will remain the same. 
  
 Amendments:

  
 1) Section 2. Position and Duties 
  
 Effective January 1, 2003, Executives title has been changed to Senior Vice
President, Strategy & Corporate Development. 
  
 Executive
has temporarily relocated to San Diego. Executive retains the right to work remotely and may choose at his discretion to relocate his residence at any time in the future. 
  
 In the event the Executive relocates to any location other than San Diego, the Executive shall spend approximately twenty
five (25%) of his working time each calendar quarter in San Diego. 
  
 2) Section 3. Base Salary and Benefits 
  
 3.(a) Effective July 28, 2003, the annual Base Salary will be adjusted to Two Hundred Thousand Dollars ($200,000) per annum. 
  
 3.(b) Eligible to receive an annual performance bonus having a target percentage up to twenty (20%) of base salary. The amount may
vary below or above this amount, however, the decision will be at the sole discretion of the CEO and Board. Executive must be employed by Proflowers on the last day of any applicable fiscal year in order to be eligible to receive a bonus.

  
 3.(e) In the event Executive relocates
back to the Boston metropolitan area, the Company shall reimburse Executive for reasonable expenses related to the actual move of his household and personal effects; reimburse Executive for reasonable expenses in traveling between Boston and San
Diego for purposes of performing his duties hereunder. In the event the Executive relocates to another area besides the Boston metropolitan area, the Company shall reimburse the Executive for reasonable expenses in traveling between his residence
and San Diego for purposes of performing his duties hereunder. 







 3) Section 4. Term 
  
 4.(e), (iv) an requirement without his consent that requires Executive to relocate or spend more than
25% of his time working outside of the city he has residence. 
  
 I have read this
amendment and agree to the terms and conditions described above in addition to the original and 1st amended
employment agreement.. 
  

	DATED:	  	 7/28/03

	  	Employee’s Signature
			
	 	  	 	  	 /s/ Jonathan Sills


		
	 Employee’s Name (Print)
	  	 JONATHAN SILLS


			
	DATED:	  	 7/28/03

	  	Proflowers.com
			
	 	  	 	  	 /s/ William Strauss


	 	  	 	  	 By: Bill Strauss
   CEO
October 21, 1959

No. 63462.

Suit 4974.

#### United States *v.*John A. Steer Co.

Abstract 62079 reversed July 10, 1959. C.A.D. 715.
01 

02

03

04

05

06

07

08

09

10

11

12

13

14

15

16

17

18

19

20

21

22

DETENTION ORDER 15.13

18 U.S.C. § 3142(i) Rev. 1/91

PAGE 1

UNITED STATES DISTRICT COURT

WESTERN DISTRICT OF WASHINGTON

AT SEATTLE

UNITED STATES OF AMERICA,

Plaintiff,

v.

JOSE MANUEL CARDENASMURATALLA,

Defendant.

____________________________________

)

)

)

)

)

)

)

)

)

)

)

CASE NO. 06-408M

DETENTION ORDER

Offense charged: 

Illegal Reentry After Deportation in violation of 8 U.S.C. § 1326(a).

Date of Detention Hearing: August 3, 2006.

The Court, having conducted a detention hearing pursuant to 18 U.S.C. § 3142(f), and

based upon the factual findings and statement of reasons for detention hereafter set forth, finds the

following:

FINDINGS OF FACT AND STATEMENT OF REASONS FOR DETENTION

(1) The Pretrial Services Report of August 3, 2006 reveals that there is an immigration

detainer lodged against the defendant.

Case 2:06-mj-00408-JPD Document 8 Filed 08/03/06 Page 1 of 3
01 

02

03

04

05

06

07

08

09

10

11

12

13

14

15

16

17

18

19

20

21

22

DETENTION ORDER 15.13

18 U.S.C. § 3142(i) Rev. 1/91

PAGE 2

(2) Defendant was born in and is a citizen of Mexico.

(3) There is no information available to show that defendant has any ties to this

community or to the Western District of Washington.

(4) Defendant has a criminal background history revealing prior charges and

convictions.

(5) Defendant is viewed as a risk of nonappearance because of the nature of the instant

charge and as a risk of danger based on his criminal history.

(6) There appear to be no conditions or combination of conditions other than detention

that will reasonably assure the defendant’s appearance at future Court hearings or the safety of the

community.

IT IS THEREFORE ORDERED:

(1) Defendant shall be detained pending trial and committed to the custody of the

Attorney General for confinement in a correction facility separate, to the extent

practicable, from persons awaiting or serving sentences or being held in custody

pending appeal;

(2) Defendant shall be afforded reasonable opportunity for private consultation with

counsel;

(3) On order of a court of the United States or on request of an attorney for the

government, the person in charge of the corrections facility in which defendant is

confined shall deliver the defendant to a United States Marshal for the purpose of

an appearance in connection with a court proceeding; and

(4) The Clerk shall direct copies of this Order to counsel for the United States, to

Case 2:06-mj-00408-JPD Document 8 Filed 08/03/06 Page 2 of 3
01 

02

03

04

05

06

07

08

09

10

11

12

13

14

15

16

17

18

19

20

21

22

DETENTION ORDER 15.13

18 U.S.C. § 3142(i) Rev. 1/91

PAGE 3

counsel for the defendant, to the United States Marshal, and to the United States

Pretrial Services Officer.

DATED this 3rd day of August, 2006.

s/ James P. Donohue 

United States Magistrate Judge

Case 2:06-mj-00408-JPD Document 8 Filed 08/03/06 Page 3 of 3
<PAGE>
                              Second Supplement to
                       Appendix A to Employment Agreement
                        Between Stewart Enterprises, Inc.
                                      and
                               Everett N. Kendrick



                  Base Salary, Bonus Compensation and Benefits
                  --------------------------------------------



2.       For Fiscal Year 2003 ("FY 2003"), the Employee shall be eligible to
         receive a Bonus of up to $275,000. For Fiscal Year 2004, the Employee
         shall be eligible to receive a Bonus of up to $300,000.

         (a) Maximum Bonus potential for FY 2003 will be determined based on the
         criteria approved by the Compensation Committee of the Board of
         Directors.


         No other items or portions of items in Appendix A as previously
         supplemented are affected by this Supplement.


                                      Agreed to and accepted:


                                      STEWART ENTERPRISES, INC.


Date:   June 25, 2003                 By: /s/ JAMES W. MCFARLAND
                                          ----------------------
                                            James W. McFarland
                                     Compensation Committee Chairman


                                      EMPLOYEE


Date:   June 25, 2003                 /s/ EVERETT N. KENDRICK
                                      ------------------------
                                         Everett N. Kendrick
Exhibit
10.26


 


AMENDMENT
TO LICENSE AGREEMENT


 


This amendment is entered
into affective as of August 2, 2000 between the President and Fellows of
Harvard College (hereinafter HARVARD) having offices at 25 Shattuck Street,
Suite 414, Boston, MA 02115 and AVANT Immunotherapeutics, Inc. (hereinafter
LICENSEE) having offices at 119 Fourth Avenue, Needham, Massachusetts 02494.


 


WHEREAS HARVARD and Virus
Research Institute (“VRI”) entered into a license agreement effective as of
May 1, 1992, and amended as of April 30, 1993, with respect to
certain patents and technology directed to cholerae and salmonella (the
“License Agreement”); and


 


WHEREAS licensee has
succeeded to VRI’s rights and obligations under the License Agreement; and


 


WHEREAS the Parties
desire to amend the License Agreement.


 


NOW THEREFORE, in
consideration of the foregoing premises, and the mutual promises and other good
and valuable consideration, the parties agree as follows:


 


1.                                       Section 6.3
of the License Agreement shall be amended by adding the following sentence at
the end of such section:


 


In the event such
surrendered PATENT RIGHTS are subject to a sublicense granted by LICENSEE,
LICENSEE shall assign LICENSEE’S interest therein upon termination of the
Agreement, subject to HARVARD’S consent, which shall not be unreasonably
withheld or delayed. In the event HARVARD shall reject such assignment, the
sublicense shall be terminated.


 


2.                                       Section 8.4
of the License Agreement is deleted in its entirety and replaced with the
following:


 


Any sublicenses granted
by LICENSEE under this Agreement shall provide (i) that LICENSEE shall assign
LICENSEE’S interest therein upon termination of the Agreement, subject to
HARVARD’S consent, which shall not be unreasonably withheld or delayed, and
(ii) that, in the event HARVARD shall reject such assignment, the sublicense
shall be terminated.


 

















 


3.                                       Except
as modified herein, the License Agreement and the terms, conditions and
obligations thereof remain in full force and effect as originally written.


 


	
  PRESIDENT AND FELLOWS OF

  HARVARD COLLEGE

  	
  AVANT IMMUNOTHERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Jeffrey
  Labovitz

  	
   

  	
  By:

  	
  /s/ Fritz
  Casselman

  	
   

  
	
   

  	
  Name:

  	
  Jeffrey Labovitz, Ph.D.

  	
   

  	
  Name:

  	
  Fritz Casselman

  
	
   

  	
  Title :

  	
  Director, Office of
  Technology

  Licensing & Industry

  Sponsored Research

  	
   

  	
  Title:

  	
  Senior Vice President,

  Strategy and Corporate

  Development

  
	
   

  	
  Date:

  	
  8/29/2000

  	
   

  	
  Date:

  	
  8/24/2000

  
								



 


2
EXHIBIT 10.11.3

                             SECOND AMENDMENT TO THE
                            UNION CARBIDE CORPORATION
                       BENEFITS PROTECTION TRUST AGREEMENT


          The Union Carbide  Corporation  Benefits Protection Trust (Amended and
Restated  Effective  August  29,  1997)  (the  "Trust")  between  Union  Carbide
Corporation  and State  Street Bank and Trust  Company,  as  Trustee,  is hereby
amended as follows:

          1.    The first sentence of Paragraph  (b) of Article  NINTH is hereby
amended to read as follows:

                 "The  Committee  shall  consist of not less than three (3)
                 members to be  appointed  by and serve at the  pleasure of
                 the Board of Directors of the Company."

          2.    The provisions of this Second Amendment shall be effective as of
August 3, 1999.


                                          UNION CARBIDE CORPORATION


                                          By:    /s/M. A. Kessinger
                                          Title: Vice President, Human Resources

                                          Date:  September 21, 1999



                                          STATE STREET BANK AND TRUST
                                           COMPANY, AS TRUSTEE


                                          By:    /s/Kelly Driscoll
                                          Title: Vice President

                                          Date:  October 7, 1999
Before the Second Division,

June 22, 1950

No. 54448.

#### Belgo-French Steel Export, Inc., et al. *v.*United States,

protests 151900-K, etc. (New York).

. Opinion by

Lawrence, J.

The protests were dismissed.
No. 67252.

protest 60/10499 (Los Angeles).

#### New York Merchandise Co., Inc. *v.*United States,

Opinion by

Oliver, C.J.

In accordance with stipulation of counsel that the merchandise consists of miniature knickknacks similar in all material respects to those the subject of Abstract 66106, the claim of the plaintiff was sustained.
Exhibit 32.2
 
 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
 Certification Pursuant to 18 U.S.C. Section 1350 (Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)
 
 In connection with the quarterly report on Form 10-Q of Chugach Electric Association, Inc. (the "Company") for the quarter ended March 31, 2011, as filed with the Securities and Exchange Commission (the "Report"), I, Michael R. Cunningham, Chief Financial Officer and Principal Financial Officer of the Company, hereby certify as the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:
 (1)
the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
 
 (2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.
 
 
 Date: May 13, 2011
/s/ Michael R. CunninghamMichael R. CunninghamChief Financial OfficerPrincipal Financial Officer